97013-79-1

Basic information

• Product Name: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline
• Synonyms: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline
• CAS NO: 97013-79-1
• Molecular Weight: 445.605
• Mol File: 97013-79-1.mol

Chemical Properties

• CAS DataBase Reference: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline(97013-79-1)
• EPA Substance Registry System: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline(97013-79-1)

Safety Data

• Hazardous Substances Data: 97013-79-1(Hazardous Substances Data)

Upstream product

• 59211-76-6 N⁽¹⁾,N⁽³⁾-3-bis(4-methoxybenzyl)propane-1,3-diamine 
• 100-10-7 4-dimethylamino-benzaldehyde 
• 6958-31-2 N,N′-bis[(4-methoxyphenyl)methlylidene]propane-1,3-diamine 
• 123-11-5 4-methoxy-benzaldehyde 
• 552859-15-1 (N¹E,N³E)-N¹,N³-bis(4-methoxybenzylidene)propane-1,3-diamine 

Relevant articles and documents

Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors

In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP 1. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP.

Synthesis, cytotoxicity, antibacterial and antileishmanial activities of imidazolidine and hexahydropyrimidine derivatives

This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the "first and second line" drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.

Synthesis, antiinflammatory and analgesic activity of new hexahydropyrimidine derivatives

A number of potentially active hexahydropyrimidine derivatives of pharmaceutical interest have been synthesized. Various diSchiff's bases prepared by reacting different aromatic aldehydes with 1,3-diaminopropane were suitably reduced to give their tetrahy